Arkolith/Insider Trading/SABS/Form 4/A

Petry John

DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4/A · filed Nov 15, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 13, 2023Grant(A)13K$1000.00$13.3M31K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001062993-23-020902) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML